Prior PRs had nothing to do with the immediately marketable value of IPIX and all prior share prices were pure BS based on certain groups running the value of the stock up and down.
This PR will establish the value of Prurisol for Psoriasis and give a pretty good indication as to whether it will work on other auto immune conditions as it is expected to do. That means P will be partnerable after this PR, whether that valuation is extremely high or moderately high being the only question. I see the chances for a failure in P2b as near zero based on the safety profile to date and efficacy showings in P2a.
The above is why the PR is so important; no longer will IPIX share price be dancing in the wind and being played by the strings of those continually screwing with the share price. They can still play games but they will play dearly for them as major buying comes in based on established value of the drug.
The other avenue of importance of the next PR is it will allow Leo to comment on what he holds for the future of IPIX in regards to succession of drugs to partner and announce near immediate partnerships to bring in needed cash and provide another solid base for IPIX in future money raising efforts if some be needed.
If someone hadn't been aware of the above regarding IPIX and this PR, they must have no clue as to what is going on with the company.
News 
Market Data 
Discover 
AI
